Response Evaluation Criteria for Solid Tumours (RECIST) were introduced in 2000 to provide a standardized method for assessing response to treatments^\[^[@B1]^\]^. The RECIST Working Group has updated RECIST to Version 1.1^\[^[@B2]^\]^. The revised version has maintained assessment of tumour burden using the sum of the diameters and continues to use uni-dimensional measurements. The response categories are still complete response, partial response (30% decrease in sum from baseline), stable disease and progressive disease (20% increase in sum from nadir). The revisions address issues that have arisen related to the use of the criteria in clinical practice. [Table 1](#T1){ref-type="table"} outlines the main changes. Table 1RECIST 1.0RECIST 1.1Tumour burdenMaximum 10 target lesions in total and up to 5 per organMaximum 5 target lesions in total and up to 2 per organMeasurable lesions≥10 mm in longest diameter (LD) for spiral CT (nodal and extranodal lesions)≥20 mm in LD for non-spiral CT≥20 mm in LD for clinical lesions≥20 mm in LD for chest radiographUltrasound (US) may be an alternative to clinical measurement of superficial nodes or nodules≥10 mm in LD and 2 time the slice thickness for extra-nodal lesions≥15 mm in short axis diameter (SAD) for nodal lesions≥10 mm in LD for clinical lesions≥20 mm in LD for chest radiographUS cannot be used to measure lesionsLymph nodesNodal lesions not distinguished from extra-nodal lesionsLymph nodes are considered abnormal enlarged if SAD \>10 mmMeasurable nodal lesions must be ≥15 mm in SADNon-measurable nodal lesions SAD \>10 mm and \<15 mmThe sum of the diameters (LD for extra-nodal target lesions and SAD for nodal lesions) is followed through treatmentComplete response (CR)CR requires disappearance of all lesionsCR requires the disappearance of all extra-nodal lesions and regression of nodal lesions to \<10 mm SADProgressive disease (PD)PD occurs if the sum of the longest diameters increases by ≥20% from nadirPD occurs if there is "unequivocal progression" of existing non-target lesionsPD occurs if the sum of the diameters has increased by ≥20% and ≥5 mm from nadirPatients with measurable disease for "unequivocal progression" based on non-target disease, there must be an overall substantial worsening that merits discontinuation of therapy (if target disease is SD/PR)Patients without measurable disease for "unequivocal progression" of non-target disease, the increase in overall tumour burden must be comparable to the increase needed for PD of measurable diseaseConfirmation of responseCR and PR require confirmation by a repeat assessment 4 weeks after initial documentationConfirmation of PR/CR is ONLY required for non-randomized trials where response is the primary end pointNew lesionNot specifically definedNew lesions should be unequivocal and not attributable to differences in scanning technique or findings which may not be tumour. If a new lesion is equivocal then repeat scans are needed to confirm. Lesions identified in anatomic locations not scanned at baseline are considered new. New lesions on US should be confirmed on CT/magnetic resonance imaging (MRI)Fluorodeoxyglucose (FDG)-positron emission tomography (PET)No specific recommendationsNew lesions can be assessed using FDG/PETPET negative at baseline and positive at follow-up is PD based on a new lesionNo PET at baseline and positive PET at follow-up is PD if the new lesion is confirmed on CTNo PET at baseline and positive PET at follow-up corresponding to a pre-existing lesion on CT that is not progressing is not PDOverall responseOverall response table integrates target, non-target and new lesionsOne overall response table integrates target, non-target and new lesionsAnother table integrates non-target and new lesions for the assessment of subjects without measurable disease[^1]

[^1]: Table modified from: <http://www.corelabpartners.com/CoreLabPartners/media/Corelab/RECIST-Guide_122011web.pdf>
